Sage Journals: Discover world-class research

Abstract

Around 70% of men presenting with prostate cancer will have organ-confined disease, with the majority presenting with low- or intermediate-risk prostate cancer. This article reviews the evidence supporting the current standard of care in radiation oncology for the evaluation and management of men with intermediate-risk prostate cancer. Dose escalation, hormonal therapy, combined modality therapy, and modern techniques for the delivery of radiation therapy are reviewed.

Keywords

prostate cancer radiation intermediate risk androgen deprivation brachytherapy external beam dose escalation outcomes review

Introduction

Prostate cancer is the most common cancer in men and the second most common cause of cancer death. Extrapolating from data gathered between 2005 and 2007, US men have a 16.2% lifetime risk of being diagnosed with prostate cancer. Around 70% of these patients will present with organ-confined disease, with the majority presenting with low- or intermediate-risk prostate cancer [Jemal et al. 2010].

Risk stratification into low-risk, intermediate-risk, and high-risk prognostic groups is based on prostate specific antigen (PSA), clinical tumor stage, and Gleason score, and dictates appropriate initial management options. Based on the work of D’Amico and colleagues, the following inclusion criteria are most commonly used to define the prognostic groups: the low-risk group includes stage T1c–T2a tumors, PSA ≤ 10 ng/ml and Gleason score ≤ 6; the intermediate-risk group includes those with stage T2b–T2c tumors, and PSA >10 but ≤20 ng/ml, and Gleason score 7; the high-risk group includes stage T3–T4 tumors, PSA > 20 ng/ml, and Gleason score 8–10 [D’Amico et al. 1998]. Intermediate-risk prostate cancer correlates with American Journal of Critical Care seventh edition group IIA [Edge et al. 2010]. Percentage of positive prostate biopsy cores, pretreatment PSA velocity, and presence or absence of perineural invasion observed on biopsy provide further prognostic information when selecting the most appropriate treatment strategy for individual patients. Patients with two or more intermediate risk factors have been noted to behave more similarly to patients at high risk [Briganti et al. 2007; D’Amico et al. 2004b, 2005]. This review focuses on the evaluation and management of men diagnosed with prostate cancer in the intermediate-risk category.

Pretreatment evaluation of patients with intermediate-risk prostate cancer

In addition to routine history and physical examination, including a digital rectal examination, serum PSA, and serum testosterone, radiographical imaging of the abdomen and pelvis using computed tomography (CT) or magnetic resonance imaging (MRI) should be obtained to assist in the evaluation of the extent of primary disease. Although the likelihood of bone metastases is low in men with intermediate-risk prostate cancer, bone scan may be appropriate for patients in whom there is high suspicion for metastatic disease based on laboratory, imaging, or clinical findings [Chybowski et al. 1991].

While CT imaging of the pelvis is the current standard, T2 MRI is superior to CT as it provides adequate soft tissue resolution to delineate the anatomy of the prostate, seminal vesicles, neurovascular bundles, and pelvic floor. MRI offers the ability to detect disease within and adjacent to the prostate gland that is not as easily visualized on CT [Flanigan et al. 1996; Heesakkers et al. 2008]. MRI, if obtained, can be fused to treatment planning CTs, allowing improved accuracy in contour definition of target and normal tissue volumes [Kagawa et al. 1997; Rasch et al. 1999; Roach, 1996]. This may result in improved clinical outcomes by decreasing normal tissue toxicity [Villeirs and De Meerleer, 2007]. MRI and magnetic resonance spectroscopy may have a role in the evaluation of tumor response to external beam radiation therapy (EBRT) and prostate brachytherapy (BRT) [Mazaheri et al. 2011; Pickett et al. 2004; Pucar et al. 2005].

Clinical trials

The rationale driving the current standard of care for intermediate-risk prostate cancer is predicated on the results of several prospective, randomized controlled trials. These trials can be generally divided into two broad categories: dose escalation trials and conventional dose radiation therapy (RT) with or without androgen deprivation trials. The most significant improvements in disease control and overall survival have been observed with the addition of neoadjuvant hormonal therapy (NHT) to conventional dose RT [Bolla et al. 2010; Crook et al. 2004, 2009; D’Amico et al. 2004a, 2008; Denham et al. 2005, 2011; Laverdiere et al. 1997; McGowan et al. 2010; Roach et al. 2008].

The dose escalation trials established that high-dose RT delivered via a conformal technique [78–81 Gray (Gy) delivered to the prostate] is well tolerated and results in significant improvement in freedom from biochemical failure and disease-free survival versus conventional dose (64–70 Gy) regimens for men with intermediate-risk prostate cancer, although it has not been shown to confer an overall survival advantage [Al-Mamgani et al. 2008; Dearnaley et al. 2007; Kuban et al. 2008; Peeters et al. 2002, 2006; Sathya et al. 2005; Shipley et al. 1995; Zietman et al. 2005, 2010]. The trials evaluating the addition of hormonal blockade to RT demonstrated improvement in local control, disease-free survival, cancer-specific survival, and overall survival. Studies are currently underway evaluating the optimal combination of dose escalation with hormonal therapy, as well as the optimal duration of androgen deprivation therapy for patients with intermediate-risk prostate cancer.

Dose-escalation trials

Prior to the advent of three-dimensional conformal RT (3DCRT), 70 Gy was established as the maximal tolerable dose due to limitations conferred by rectal and bladder toxicity [Lawton et al. 1991; Pilepich et al. 1987b]. With improved dose conformality, the ability to safely deliver higher doses to the prostate was established, and resultant improvements, especially in biochemical progression-free survival, were seen.

MD Anderson Cancer Center 93-002

This trial evaluated the effect of dose escalation from 70 to 78 Gy on freedom from failure, and was among the first to include biochemical (PSA) freedom from failure as an endpoint. Between 1993 and 1998, 301 patients with T1–T3 tumors, including 139 patients with intermediate-risk cancer, were randomized to receive 70 or 78 Gy via EBRT to the prostate gland. All patients received an initial 46 Gy in 2 Gy daily fractions via a four-field box technique. Following delivery of 46 Gy, each group received a 3DCRT boost commensurate with their remaining prescribed total dose, such that the conventional dose arm received an additional 24 Gy via a four-field technique, and the high-dose arm received a 32 Gy boost via a six-field technique. At 8-year follow up, freedom from biochemical failure favored the 78 Gy arm, 59% versus 78% (p = 0.04). The subset of patients with an initial PSA of more than 10 ng/ml gained the greatest benefit from dose escalation with 78% versus 39% freedom from failure (p < 0.001). Among patients with intermediate-risk cancer, the subset with pretreatment PSA greater than 10 ng/ml similarly benefitted most substantially from dose escalation, with biochemical freedom from failure of 94% versus 65% (p = 0.076) [Kuban et al. 2008; Pollack et al. 2002]

Notably, the rate of Radiation Therapy Oncology Group (RTOG) grade 2 or greater rectal toxicity was 14% higher in the 78 Gy arm and was found to correlate with the volume of rectum receiving at least 70 Gy [Kuban et al. 2008]

Proton Radiation Oncology Group 95–09

This trial evaluated the effect of dose escalation from 70.2 to 79.2 Gray equivalents (GyE) on local failure, biochemical failure, and overall survival in patients with localized prostate cancer. A total of 393 patients with stage T1b–T2b prostate cancer and PSA levels less than 15 ng/ml were randomized to receive EBRT to a total dose of either 70.2 or 79.2 GyE delivered via conformal photon therapy with conformal proton boost. The prostate gland plus a 12–15 mm margin received a conformal proton dose of 19.8 or 28.8 GyE in 1.8 GyE fractions. Subsequent to initial proton treatment, all patients received 50.4 Gy to the prostate gland and seminal vesicles plus a 10 mm margin via a conformal four-field technique. At 10-year follow up, biochemical failure rates were halved from 32.3% for the conventional dose arm to 16.7% for the dose-escalated arm. High-dose therapy conferred improved outcomes in all risk groups, though this was only statistically significant for those with low-risk disease (58% of the cohort) in which 28.2% of those receiving conventional dose therapy failed versus 7.1% of those receiving high-dose therapy (p = 0.0001). Patients with intermediate-risk cancer trended toward a benefit with high-dose RT, though the study was not powered to detect differences on subgroup analysis, and this result did not reach statistical significance. Patients with intermediate-risk cancer represented 37% of the cohort. Of these patients, 42.1% receiving conventional dose therapy failed to respond versus 30.4% who received the dose-escalated regimen (p = 0.06) [Shipley et al. 1995; Zietman et al. 2010].

Dutch Trial CKTO 6910

This trial was conducted to evaluate the effect of dose escalation from 68 to 78 Gy on freedom from failure. To that end, 669 patients with stage T1b–T4 prostate cancer at four institutions in the Netherlands were randomized to receive either 68 or 78 Gy via a 3DCRT technique. The clinical target volume (CTV) included the prostate plus or minus the seminal vesicles depending on assessed risk for seminal vesicle involvement based on the Partin method. Planning target volume (PTV) included a 10 mm expansion for the initial 68 Gy for all patients, followed by an additional 10 Gy with 5 mm expansion, except 0 mm toward the rectum, for patients receiving 78 Gy. In two institutions, neoadjuvant hormone therapy was prescribed for some, mostly patients with high-risk cancer. The study was not statistically powered to detect a difference due to the addition or withholding of hormonal therapy. With 4 years of follow up, the freedom from biochemical failure was 64% in the high-dose arm versus 54% in the low-dose arm (p = 0.02). There was no significant difference in overall survival between the treatment arms. For patients with intermediate-risk cancer, there was a statistically significant 15% improvement in freedom from failure in the high-dose arm [Peeters et al. 2006].At 70 months of follow up, the 7-year biochemical control rates continued to favor the high-dose arm, 56% versus 45%, p = 0.03. The cumulative incidence of late grade 2 or greater gastrointestinal (GI) toxicity manifested by rectal bleeding and incontinence was increased in the 78 Gy arm compared with the 68 Gy arm (35% versus 25% at 7 years; p = 0.04) [Al-Mamgani et al. 2008]

Medical Research Council RT01 trial

This trial sought to evaluate whether NHT combined with dose-escalated RT (74 Gy versus 64 Gy) would improve cancer control as measured by biochemical progression-free survival, freedom from local progression, metastasis-free survival, and overall survival, without a prohibitive increase in treatment-associated toxicity compared with NHT followed by standard dose RT. This is the largest randomized prospective dose-escalation trial, and the only one to prescribe NHT uniformly to all patients.

A total of 843 men with stage T1b–T3a, N0, M0 prostate cancer, and serum PSA of less than 50 ng/ml first received between 3 and 6 months of NHT and were randomly assigned to receive 64 Gy over 32 fractions in 6.5 weeks or 74 Gy over 37 fractions in 7.5 weeks.

The gross tumor volume for all patients included the prostate gland and all or a portion of the seminal vesicles, depending on the risk group. In patients with low-risk cancer, gross tumor volume (GTV) included the base of the seminal vesicles, and in patients with intermediate- and high-risk cancer, all of the seminal vesicles. A 5 mm expansion was made from GTV to CTV and a subsequent 5 mm to 1 cm expansion from CTV was made to PTV. Biochemical progression-free survival at 5 years (63 months average) favored the patients on dose-escalation therapy across all risk groups, 71% versus 60% (p = 0.0007), and in the intermediate-risk group, by 9 percentage points (79% versus 70%). There was no observed difference in freedom from local progression or overall survival. There was an increased incidence of late GI toxicity and genitourinary (GU) toxicity in the 74 Gy arm [Dearnaley et al. 2007].

As a group, these trials demonstrated a benefit for dose-escalated RT for intermediate-risk prostate cancer in terms of biochemical freedom from failure and local control, but failed to demonstrate an improvement in overall survival. Table 1 summarizes the outcomes of the dose-escalation trials. Overall, GI and GU toxicity in the high-dose arms were increased versus The conventional dose arms, with the exception of those treated with protons. A caveat is that these trials were conducted prior to the advent of intensity modulated RT (IMRT) or did not allow this therapy, which has permitted substantial improvements in the conformality of delivered doses and resultant reduction in normal tissue dose profiles and toxicity. The results of RTOG 0126 will provide prospective evaluation of toxicity and survival outcomes for dose escalation to 79.2 Gy versus 70.2 Gy delivered via a 3DCRT/IMRT technique for patients with intermediate-risk cancer.

Table 1.

Dose escalation trials.

Study	No.	Risk groups	Dose levels	Outcome	p value
MDACC 93-002	301	LR: 61	78 Gy	8-year bNED 78%	0.004
		IR: 139	70 Gy	8-year bNED 59%
		HR: 101
PROG 95-09	392	LR: 227	79.2 GyE	5-year bNED 80%	< 0.001
		IR: 129	70 GyE	5-year bNED 61%
		HR: 33
NCI CKTO	664	LR: 120	78 Gy	5-year FFF 64%	0.01
		IR: 182	68 Gy	5-year FFF 54%
		HR: 362
MRC RT 01	843	LR: 204	NHT + 74 Gy	5-year bPFS 71%	0.0007
		IR: 264	NHT + 64 Gy	5-year bPFS 60%
		HR: 362

bNED, biochemically no evidence of disease; bPFS, biochemical progression-free survival; FFF, freedom from failure; HR, high risk; IR, intermediate risk; LR, low risk; MDACC, MD Anderson Cancer Center; MRC, Medical Research Council; NCI, National Cancer Institute; NHT, neoadjuvant hormonal therapy; PROG, Proton Radiation Oncology Group.

Radiation therapy with or without hormonal therapy

Dana Farber Cancer Institute Trial

This trial sought to evaluate the effect of the addition of androgen deprivation therapy to RT on survival, disease-specific mortality, survival free from salvage hormonal therapy, and all-cause mortality. To this end, 206 men with T1b–T2b, N0, M0 adenocarcinoma of the prostate and either a Gleason score of at least 7 (5–10), a serum PSA of at least 10 ng/ml, or, in patients with low-risk cancer, MRI evidence of extra-prostatic disease or seminal vesicle invasion, were randomized to receive 70 Gy via 3DCRT alone or in combination with 6 months of androgen suppression therapy (AST). All patients received an initial 45 Gy to the prostate and seminal vesicles followed by an additional 25.35 Gy boost to the prostate plus a 1.5 cm margin via a four-field 3DCRT technique. Leuprolide or goserelin were used in combination with flutamide to achieve androgen blockade. At a median 4.52 years of follow up, patients randomized to receive combined modality therapy (CMT) had significantly higher survival, lower prostate-cancer-specific mortality, and higher survival free of salvage hormonal therapy. Five-year survival rates favored CMT by 10 percentage points (88% versus 78%). At 7.6 years of follow up, the Kaplan–Meier 8-year survival estimates were 74% and 61% respectively for patients receiving AST versus those receiving RT alone. The increased risk in all-cause mortality was significant only in those patients randomized to RT with or without minimal comorbid pretreatment disease [D’Amico et al. 2004a, 2008].

Radiation Therapy Oncology Group 94-08

This multi-institutional study was conducted to evaluate the effect of the addition of AST to RT on overall survival, freedom from biochemical failure, freedom from clinical progression, and disease-free survival in patients with localized prostate cancer in response to the positive effect on these parameters seen in RTOG 86-10. To this end, 1979 patients with T1b–T2b prostate cancer and PSA less than 20 ng/ml were randomized to receive EBRT alone or in conjunction with 2 months of neoadjuvant and 2 months of concurrent goserelin and flutamide.

Table 2.

Radiation treatment with and without hormonal therapy trials.

Study	No.	Risk groups	Treatment arms	Outcome	p value
Dana-Farber	206	LR: 5	67.5 Gy versus	5-year OS 88%	0.04
Dana-Farber	206	IR/HR: 201	6 months NHT + 67.5 Gy	5-year OS 78%	0.04
RTOG 94-08	1979	LR: 685	66.6/ 68.4 Gy versus	5-year OS 87%	0.031
		IR: 1068	4 months NHT + 66.6/68.4 Gy	5-year OS 79%
		HR: 226	4 months NHT + 66.6/68.4 Gy	5-year OS 79%
TROG 96.01	802	IR:130	66 Gy versus 3 or 6 months NACHT	10-year OS	0.18 (3 months ADT + RT versus RT alone)
		HR:672		57.5% (RT)	0.18 (3 months ADT + RT versus RT alone)
				10-year OS	0.0008
				63.3% (3 months)	(6 months ADT + RT versus RT alone)
				10-year OS 79.8% (6 months)	(6 months ADT + RT versus RT alone)

ADT, androgen deprivation therapy; HR, high risk; IR, intermediate risk; LR, low risk; NACHT, neo adjuvant concurrent hormonal therapy; NHT, neoadjuvant hormonal therapy; OS, overall survival; RT, radiation therapy; RTOG, Radiation Therapy Oncology Group; TROG, Trans-Tasman Radiation Oncology Group.

All patients received 46.8 Gy in 26 1.8 Gy fractions to the regional lymphatics followed by 19.8 Gy in 1.8 Gy fractions to the prostate alone for a total of 66.6 Gy. At 8 years of follow up, the overall survival rate was 62% with combined therapy and 57% with RT alone. The benefit was most pronounced in patients with intermediate-risk cancer receiving CMT, who had an overall survival rate of 72% (versus 66% in the RT alone arm), disease-specific survival of 98% (versus 92%), a biochemical control rate of 75% (versus 58%), and a number needed to treat of 17. The overall survival rate was 66% versus 58%, favoring CMT in patients with high-risk cancer, and was not statistically significant (76% versus 73%) in patients with low-risk cancer [McGowan et al. 2010].The 10-year death rate excluding deaths from prostate cancer was 35% in the CMT and 37% in the radiation-only arms, supporting the conclusion that the addition of short-course hormonal blockade to RT did not increase the risk of death from comorbid disease [McGowan et al. 2010].

Trans-Tasman Radiation Oncology Group 96.01

This trial sought to evaluate the effect of the addition of androgen deprivation therapy of 0, 3, or 6 months to RT on time to local failure, prostate-cancer-specific survival, distant failure, disease-free survival, and freedom from salvage treatment for patients with locally advanced prostate cancer. A total of 802 evaluable men with T2b, T2c, T3, or T4, N0, M0 prostate cancer were randomized to receive one of three treatment regimens: 66 Gy in 33 fractions to the prostate and seminal vesicles alone; 66 Gy plus 3 months of neoadjuvant and concurrent ADT; or 3. 66 Gy plus 6 months of neoadjuvant and concurrent ADT. ADT was with goserelin and flutamide. At a median follow up of 5.9 years, the results of this trial showed a benefit for 3 or 6 months of neoadjuvant ADT in terms of distant failure-free, prostate-cancer-specific survival, local control, biochemical failure-free survival, disease-free survival, and freedom from salvage treatment versus RT alone. The results were not consistent between the 3- and 6-month groups, and favored 6 months of neoadjuvant and concurrent ADT with RT [Denham et al. 2005].

At 10.6-year median follow up, both CMT arms showed benefit in freedom from biochemical progression, freedom from local failure, and event-free survival compared with RT alone. Greater improvement was again seen for 6 months versus 3 months of CMT for each of these parameters. Six months of CMT additionally conferred improved freedom from distant progression, prostate-cancer-specific mortality, and overall survival while no improvement was seen in these parameters with 3 months of CMT [Denham et al. 2011].

No increase in treatment-related morbidity was seen with CMT.

Hypofractionation, stereotactic body radiation therapy and high-dose rate monotherapy

Hypofractionation for the treatment of prostate cancer has recently experienced renewed interest based on radiobiological properties of tumor cells and resultant theoretical improvements in the therapeutic ratio with increased fraction sizes. While most tumors have α/β ratios around 8, prostate cancer cells are postulated to have an α/β ratio of 2. As the rectum is the major dose-limiting structure for the delivery of radiation to the prostate, and has a higher α/β ratio estimated at 4–6, it follows that hypofractionation should permit greater tumor killing without an attendant increase in the incidence of late toxicity [Brenner et al. 2002; Fowler et al. 2003]. Several randomized and nonrandomized trials have demonstrated the feasibility, tolerability, and noninferiority of hypofractionated regimens [Kupelian et al. 2007; Martin et al. 2007; Norkus et al. 2009a, 2009b; Pollack et al. 2006].

In a representative single institution series from the Cleveland Clinic, 770 patients received 70 Gy over 28 fractions via an IMRT technique. At 45 months of median follow up biochemical control rates were 94% in low-risk, 83% in intermediate-risk, and 72% in high-risk groups. There was no increase in acute or late GI or GU toxicity [Kupelian et al. 2007].

Based on the same radiobiological principles, and in concert with the development of emerging technologies and patient preferences, limited initial single institution experiences with stereotactic body RT (SBRT) and high-dose rate (HDR) monotherapy approaches to extreme hypofractionation have shown promising results but require further evaluation [Aluwini et al. 2010; Boike et al. 2011; Buyyounouski et al. 2010; King et al. 2009; Macías and Biete, 2009; Madsen et al. 2007].

Low-dose rate brachytherapy

Permanent prostatic seed implantation with iodine-125 (I-125) or palladium-103 (Pd-103) sources confers excellent tumor control and survival outcomes with minimal toxicity in the treatment of patients with early and intermediate-risk prostate cancer. Generally, patients with low-risk prostate cancer, prostates less than 50 cm³, and low International Prostate Symptom Score (IPSS) scores are eligible for primary BRT, while patients with intermediate-risk prostate cancer with similar physical characteristics are eligible for a BRT boost following EBRT to the pelvis. Innovations in treatment planning and delivery for BRT including transrectal ultrasound, template-based transperineal implantation, real-time treatment planning, and CT-based postimplant dosimetry evaluation ensure accurate dose delivery and avoidance of dose to normal tissue. Unlike external beam techniques, BRT dosimetry is not subject to intratreatment variability due to movement of the internal anatomy.

In patients with intermediate-risk prostate cancer, prostate BRT is recommended for use only as a boost therapy following EBRT. A standard regimen delivers 45 Gy to the pelvis via an external beam technique and subsequent implantation of I-125 or Pd-103 seed sources into the prostate. The Seattle Prostate Institute reported their long-term experience treating 223 patients with T1–T3 prostate cancer with an I-125 or Pd-103 PPI boost at a median interval of 4 weeks following 45 Gy delivered via EBRT to the prostate gland and seminal vesicles. The Pd-103 boost prescribed 100 Gy and the I-125 boost prescribed 108 Gy. At 15-year follow up, biochemical relapse-free survival for patients with low-risk, intermediate-risk and high-risk cancer was 88%, 80%, and 53% respectively [Sylvester et al. 2003, 2007].

A representative series comparing the effects of dose escalation for localized prostate cancer treatment with IMRT or permanent transperineal BRT versus conventional dose 3DCRT was published by Wong and colleagues from the Mayo Clinic Scottsdale. Of 853 evaluated patients, 270 received conventional dose 3DCRT, 314 received high-dose IMRT, 225 received BRT, and 44 received EBRT plus BRT boost. The median radiation doses were 68.4 Gy for 3DCRT and 75.6 Gy for IMRT. Patients receiving BRT had a prescribed dose of 144 Gy with I-125 or 120 Gy with Pd-103 respectively. Patients treated with EBRT plus BRT received 45 Gy of EBRT plus a boost of 110 Gy with I-125 or 90 Gy with Pd-103. At a median follow up of 58 months, the 5-year biochemical control rates were 74% for 3DCRT, 87% for IMRT, 94% for BRT, and 94% for EBRT plus BRT (p < 0.0001). For the intermediate-risk group, high-dose IMRT, BRT, or EBRT plus BRT achieved significantly better biochemical control rates than 3DCRT (p < 0.0001) [Wong et al. 2009].

The absence of randomized controlled data supporting improvement in outcome versus other available treatment modalities and the high cost of combination therapy are relative arguments against the use of BRT boost.

High-dose rate brachytherapy boost

As discussed above, the low α/β ratio for prostate cancer relative to the dose-limiting rectum confers an improved therapeutic ratio with the higher doses per fraction delivered via HDR. HDR versus LDR brachytherapy allows elimination of radiation exposure to patient contacts, shorter overall treatment times, and the opportunity to optimize dose distribution by varying source dwell times and positions within the target volume. Ten-year outcomes of 22–24 Gy delivered via iridium-192 after loading following 36 Gy EBRT were published by Demanes and colleagues from the California Endocurietherapy Cancer Center. Biochemical progression-free survival was 90%, 87%, and 69% for patients with low-, intermediate-, and high-risk cancer, respectively [Demanes et al. 2005]. Vargas and colleagues reported 5-year results of a prospective trial conducted at William Beaumont Hospital evaluating high-dose versus low-dose HDR boost following 46 Gy of pelvic irradiation for patients with intermediate- and high-risk prostate cancer. The HDR group received more than 268 Gy biologically equivalent dose (BED) boost between 17.5 and 23 Gy in two fractions and the LDR group received less than 268 Gy BED between 16.5 Gy in three fractions and 16.5 Gy in two fractions to the prostate. Five-year biochemical failure favored the high-dose group (68.7% versus 86%, p < 0.001), as did clinical event free survival (75.5% versus 91.7%, p = 0.003), cause-specific survival (95.4% versus 100%, p = 0.02), and overall survival (86.2% versus 97.8%, p = 0.002) [Vargas et al. 2006]. A median 8.2-year follow up of 472 patients from the same institution demonstrated a continued advantage to the HDR group from the perspective of biochemical failure, 43.1% versus 18.9% (p < 0.001), clinical failure, 23.4% versus 7.7% (p < 0.001), and distant metastasis, 12.4% versus 5.7% (p = 0.028) [Martinez et al. 2011].

Toxicity of radiation therapy and hormone therapy

RT is generally well tolerated, with certain prognostic factors such as prior transurethral resection of prostate, pretreatment IPSS score, American Urological Association score, anticoagulant use, inflammatory bowel disease, and radiation technique predicting an increased propensity to develop complications. Commonly reported acute symptoms include urinary frequency, urgency, nocturia, diarrhea, and tenesmus. These symptoms are usually well controlled with supportive care, α blockers, loperamide and steroid suppositories, and resolve shortly after completion of therapy. Urethral strictures, hematuria, hematochezia, proctitis, and incontinence occur infrequently at 1–3 years post treatment. Urethral dilatation, argon plasma laser coagulation, formalin therapy and hyperbaric oxygen have been reported as effective treatments for these late toxicities. Improvements in toxicity profiles have been demonstrated for advances in RT technologies, and are summarized below.

Toxicity of conventional two-dimensional planning

Over 1000 patients treated on RTOG trials 7506 and 7706 were followed for a minimum of 7 years and had a reported incidence of at least grade 3 bowel complications of 3.3% and a reported incidence of grade 3 or greater urinary complications in 7.7% of patients. These trials established 70 Gy as the maximal tolerable dose prior to the advent of conformal planning techniques [Pilepich et al. 1987a, 1987b]

Toxicity of three-dimensional conformal radiotherapy

RTOG 9406 evaluated the development of grade 3 or greater GI or GU toxicity in five dose levels from 68.4 to 79.2 Gy delivered via a 3DCRT technique. Group 1 patients had no elective seminal vesicle irradiation. Group 2 patients received treatment of the prostate and seminal vesicles with 54–55.8 Gy followed by a prostate boost. Rates of grade 2 or greater GI toxicity rates were 9%, 7%, 11%, 10%, and 25% for group 1 and 13%, 9%, 14%, 16%, and 26% for group 2 at 68.4 in 1.8 Gy fractions, 73.8 Gy in 1.8 Gy fractions, 79.2 Gy in 1.8 Gy fractions, 74.0 Gy in 2.0 Gy fractions, and 78.0 Gy in 2.0 Gy fractions respectively. The incidence of grade 2 or greater GU toxicity were 24%, 22%, 18%, 29%, and 23% for group 1 and 19%, 16%, 21%, 21%, and 28% for group 2. This trial demonstrated the reduction in toxicity, particularly in grade 3 or greater toxicity, despite radiation doses that were more than 10 Gy higher when conformal techniques were used [Michalski et al. 2010].

Toxicity of intensity-modulated radiation therapy

Similar to the improvements seen with the advent of 3DCRT versus conventionally planned two-dimensional RT (2DRT), IMRT techniques have allowed the same or higher radiation doses to be delivered with a reduction in grade 2 and grade 3 urinary and rectal complications. As detailed by Zelefsky and colleagues, 561 patients treated with IMRT at Memorial Sloan Kettering Cancer Center to 81 Gy had an 8-year likelihood of developing grade 2 rectal toxicity of 1.6%. Eight-year grade 2 or 3 urinary toxicity rates were 9% and 3% respectively [Zelefsky et al. 2006].

Toxicity of brachytherapy

Urinary obstructive symptoms due to inflammation and irritation of the prostate gland caused by procedure-related trauma and bleeding immediately after, and later due to radiation effect, are the most commonly reported adverse sequelae of brachytherapy. Inflammatory symptoms due to radiation are temporally related to the half life of the implanted isotope. The average onset is 1 month post procedure and symptoms peak between that time and 4 months post treatment. Treatment with α blockers and nonsteroidal anti-inflammatory drugs are sufficient to address symptoms in most patients. Acute urinary retention occurs in the immediate post-procedure period and ranges from 5% to 15% depending on preimplant lower urinary tract symptom scores and prostate volume [Crook et al. 2002]. The incidence of urethral strictures is reported to be between 2% and 12% of patients following prostate BRT [Landis et al. 2002]. Grade 2 rectal toxicity has been reported to be between 2% and 10%. Higher grade urinary or rectal toxicity is less than 2% [Stone and Stock, 2002]. Erectile dysfunction occurs in 40–50% of patients, of whom approximately 80% can be effectively treated with sildenafil citrate [Landis et al. 2002; Merrick et al. 2000, 2003; Stone and Stock, 2002].

Second malignancies

RT is known generally to be associated with an increased risk for the development of second primary cancers within the radiation field. This is particularly true for young patients with long post-treatment survival. For patients with prostate cancer, particularly in the era of modern RT techniques, the increased risk of second primary cancer is not yet known. A matched pair retrospective study comparing 2120 patients receiving RT at a single institution on a 1:1 basis with surgical patients according to age and follow-up time was recently reported. RT techniques consisted of conventional or 2DRT (36%), 3DCRT and IMRT (29%), BRT (16%), and a combination of 2DRT and brachytherapy (BT) (19%).

They found that the overall risk of developing a second primary cancer was not significantly different between the matched pair [hazard ratio (HR) 1.14, 95% confidence interval (CI) 0.94–1.39]. Additionally, they noted that the risk became significant more than 5 years (HR 1.86, 95% CI 1.36–2.55) or more than 10 years after RT (HR 4.94, 95% CI 2.18–11.2). The most significant sites of increased risk were bladder, lymphoproliferative, and sarcoma. Of the different RT techniques, only 2DRT was associated with a significantly higher risk (HR 1.76, 95% CI 1.32–2.35), but not BT boost (HR 0.83, 95% CI 0.50–1.38), 3DCRT/IMRT (HR 0.81, 95% CI 0.55–1.21), or BT (HR 0.53, 95% CI 0.28–1.01) [Huang et al. 2011].

Androgen deprivation therapy

Commonly reported side effects of ADT include fatigue, hot flashes, osteoporosis, weight gain, loss of libido, gynecomastia, erectile dysfunction, and anemia [Sharifi et al. 2005]. Less commonly reported adverse sequelae include loss of muscle mass, hypogonadism, hyperlipidemia, hyperglycemia, cardiac events, deep vein thrombosis, and depression [Bolla et al. 2007]. Supplemental vitamin D and calcium, and a prescribed diet and exercise regimen have been found to be beneficial for these patients. Long-term data from randomized trials have not shown an increase in cardiovascular mortality rates among patients receiving short-term (4–6 months) or long-term (2–3 years) AST with RT [Bolla et al. 2002; Efstathiou et al. 2008, 2009].

Conclusions

Evidence supports that patients with intermediate-risk prostate cancer have an overall survival benefit when treated with NHT and conventional dose RT versus conventional dose radiation therapy, and they have a benefit in biochemical freedom from failure when treated with a dose of 78–81 Gy versus 70 Gy RT. The role of hormonal therapy in the context of dose-escalated RT, including optimal duration of hormonal therapy and optimal dose of radiation when given with hormonal therapy, remain unclear, though studies have been completed or are underway that will help to clarify these questions. HDR and LDR boost may confer similar biochemical freedom from failure with shorter treatment times and fewer side effects, though at significantly higher cost. Hypofractionation may also confer equivalent or improved outcomes, in this case with shorter treatment times and at lower cost, but requires further evaluation. A multitude of modern therapeutic modalities exist that can technically deliver highly conformal radiation to the prostate, but phase III evidence is lacking to demonstrate superiority of one technique compared with another. The use of RT technologies should be based on prospective assessment of quality of life and modeling of cost effectiveness.

Emerging therapeutic modalities such as SBRT and HDR BRT monotherapy are promising areas of future investigation, especially given confirmatory evidence regarding the α/β ratio in prostate cancer. Highly conformal treatment delivery techniques, improved intratreatment evaluation, and improved pretreatment target localization and registration have significantly decreased the incidence of serious toxicity secondary to RT.

Footnotes

The views expressed in this presentation are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, or the United States government.

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

DG is a military service member (or employee of the US Government). This work was prepared as part of his official duties. Title 17, USC, §105 provides that ‘Copyright protection under this title is not available for any work of the US Government’. Title 17, USC, §101 defines a US Government work as a work prepared by a military service member or employee of the US Government as part of that person’s official duties.

References

Al-Mamgani

Van Putten

W.L.J.

Heemsbergen

W.D.

Van Leenders

G.J.L.H.

Slot

Dielwart

M.F.H.

. (2008) Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. IntJ Radiat Oncol Biol Phys 72: 980–988.

Aluwini

van Rooij

Hoogeman

Bangma

Kirkels

W.J.

Incrocci

. (2010) CyberKnife stereotactic radiotherapy as monotherapy for low-to intermediate-stage prostate cancer: early experience, feasibility, and tolerance. J Endourol 24: 865–869.

Boike

T.P.

Lotan

Cho

L.C.

Brindle

DeRose

Xie

X.J.

. (2011) Phase I dose-escalation study of stereotactic body radiation therapy for low-and intermediate-risk prostate cancer. J Clin Oncol 29: 2020–2026

Bolla

Collette

Blank

Warde

Dubois

J.B.

Mirimanoff

R.O.

. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. The Lancet 360: 103–108.

Bolla

Descotes

J.L.

Artignan

Fourneret

(2007) Adjuvant treatment to radiation: combined hormone therapy and external radiotherapy for locally advanced prostate cancer. BJU Int 100: 44–47.

Bolla

Van Tienhoven

Warde

Dubois

J.B.

Mirimanoff

R.O.

Storme

. (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 11: 1066–1073.

Brenner

D.J.

Martinez

A.A.

Edmundson

G.K.

Mitchell

Thames

H.D.

Armour

E.P.

(2002) Direct evidence that prostate tumors show high sensitivity to fractionation (low [alpha]/[beta] ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52: 6–13.

Briganti

Chun

F.K.H.

Hutterer

G.C.

Gallina

Shariat

S.F.

Salonia

. (2007) Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. Eur Urol 52: 733–745.

Buyyounouski

M.K.

Price

R.A.

Harris

E.E.R.

Miller

Tomé

Schefter

. (2010) Stereotactic body radiotherapy for primary management of early-stage, low-to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol Biol Phys 76: 1297–1304.

10.

Chybowski

Keller

Bergstralh

Oesterling

(1991) Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 145: 313.

11.

Crook

Ludgate

Malone

Lim

Perry

Eapen

. (2004) Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 60: 15–23.

12.

Crook

Ludgate

Malone

Perry

Eapen

Bowen

. (2009) Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 73: 327–333.

13.

Crook

McLean

Catton

Yeung

Tsihlias

Pintilie

(2002) Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 52: 453–460.

14.

D’Amico

A.V.

Chen

M.H.

Renshaw

A.A.

Loffredo

Kantoff

P.W.

(2008) Androgen suppression and radiation vs radiation alone for prostate cancer. JAMA 299: 289–295.

15.

D’Amico

A.V.

Manola

Loffredo

Renshaw

A.A.

DellaCroce

Kantoff

P.W.

(2004a) 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer. JAMA 292: 821–827.

16.

D’Amico

A.V.

Renshaw

A.A.

Cote

Hurwitz

Beard

Loffredo

. (2004b) Impact of the percentage of positive prostate cores on prostate cancer–specific mortality for patients with low or favorable intermediate-risk disease. J Clin Oncol 22: 3726–3732.

17.

D’Amico

A.V.

Renshaw

A.A.

Sussman

Chen

M.H.

(2005) Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294: 440–447.

18.

D’Amico

A.V.

Whittington

Malkowicz

S.B.

Schultz

Blank

Broderick

G.A.

. (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280: 969–974.

19.

Dearnaley

D.P.

Sydes

M.R.

Graham

J.D.

Aird

E.G.

Bottomley

Cowan

R.A.

. (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8: 475–487.

20.

Demanes

D.J.

Rodriguez

R.R.

Schour

Brandt

Altieri

(2005) High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy’s 10-year results. Int J Radiat Oncol Biol Phys 61: 1306–1316.

21.

Denham

J.W.

Steigler

Lamb

D.S.

Joseph

Mameghan

Turner

. (2005) Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6: 841–850.

22.

Denham

J.W.

Steigler

Lamb

D.S.

Joseph

Turner

Matthews

. (2011) Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 12: 351–259.

23.

Edge

S.B.

Byrd

D.R.

Compton

C.C.

Fritz

A.G.

Greene

F.L.

Trotti

(eds) (2010) AJCC Cancer Staging Manual (7th ed.). New York: Springer.

24.

Efstathiou

J.A.

Bae

Shipley

W.U.

Hanks

G.E.

Pilepich

M.V.

Sandler

H.M.

. (2008) Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 54: 816–824.

25.

Efstathiou

J.A.

Bae

Shipley

W.U.

Hanks

G.E.

Pilepich

M.V.

Sandler

H.M.

. (2009) Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 27: 92–99.

26.

Flanigan

R.C.

McKay

T.C.

Olson

Shankey

T.V.

Pyle

Waters

W.B.

(1996) Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy. Urology 48: 428–432.

27.

Fowler

J.F.

Ritter

M.A.

Chappell

R.J.

Brenner

D.J.

(2003) What hypofractionated protocols should be tested for prostate cancer?*. Int J Radiat Oncol Biol Phys 56: 1093–1104.

28.

Heesakkers

R.A.M.

Hovels

A.M.

Jager

G.J.

van den Bosch

Witjes

J.A.

Raat

H.P.J.

. (2008) MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 9: 850–856.

29.

Huang

Kestin

L.L.

Wallace

Martinez

A.A.

Vicini

F.A.

(2011) Analysis of second malignancies after modern radiotherapy versus prostatectomy for localized prostate cancer. Radiother Oncol 98: 81–86.

30.

Jemal

Siegel

Ward

(2010) Cancer statistics. CA Cancer J Clin 60: 277–300.

31.

Kagawa

Lee

W.R.

Schultheiss

T.E.

Hunt

M.A.

Shaer

A.H.

Hanks

G.E.

(1997) Initial clinical assessment of CT-MRI image fusion software in localization of the prostate for 3D conformal radiation therapy. Int J Radiat Oncol Biol Phys 38: 319–325.

32.

King

C.R.

Brooks

J.D.

Gill

Pawlicki

Cotrutz

Presti

J.C.

Jr . (2009) Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 73: 1043–1048.

33.

Kuban

D.A.

Tucker

S.L.

Dong

Starkschall

Huang

E.H.

Cheung

M.R.

. (2008) Long-term results of the MD Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70: 67–74.

34.

Kupelian

P.A.

Willoughby

T.R.

Reddy

C.A.

Klein

E.A.

Mahadevan

(2007) Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 68: 1424–1430.

35.

Landis

Wallner

Locke

Ellis

Russell

Cavanagh

. (2002) Late urinary function after prostate brachytherapy. Brachytherapy 1: 21–26.

36.

Laverdiere

Gomez

J.L.

Cusan

Raul Suburu

Diamond

Lemay

. (1997) Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys37: 247–252.

37.

Lawton

C.A.

Won

Pilepich

M.V.

Asbell

S.O.

Shipley

W.U.

Hanks

G.E.

. (1991) Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 21: 935–939.

38.

Macías

Biete

(2009) Hypofractionated radiotherapy for localised prostate cancer. Review of clinical trials. Clin Transl Oncol 11: 437–445.

39.

Madsen

B.L.

Hsi

R.A.

Pham

H.T.

Fowler

J.F.

Esagui

Corman

(2007) Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 67: 1099–1105.

40.

Martin

J.M.

Rosewall

Bayley

Bristow

Chung

Crook

. (2007) Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 69: 1084–1089.

41.

Martinez

A.A.

Gonzalez

Ghilezan

Shetty

Kernen

. (2011) Dose escalation improves cancer-related events at 10 years for intermediate-and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys 79: 363–370.

42.

Mazaheri

Shukla Dave

Muellner

Hricak

(2011) MRI of the prostate: clinical relevance and emerging applications. J Magn Reson Imaging 33: 258–274.

43.

McGowan

D.G.

Hunt

Jones

C.U.

Amin

Leibenhaut

M.H.

Husian

S.M.

. (2010) Short-term endocrine therapy prior to and during radiation therapy improves overall survival in patients with T1b–T2b adenocarcinoma of the prostate and PSA </=20: initial results of RTOG 94-08. Int J Radiat Oncol Biol Phys 77: 1–4.

44.

Merrick

G.S.

Butler

W.M.

Lief

J.H.

Dorsey

A.T.

(2000) Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 47: 121–128.

45.

Merrick

G.S.

Wallner

K.E.

Butler

W.M.

(2003) Minimizing prostate brachytherapy-related morbidity. Urology 62: 786–792.

46.

Michalski

J.M.

Bae

Roach

Markoe

A.M.

Sandler

H.M.

Ryu

. (2010) Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose-escalation study. Int J Radiat Oncol Biol Phys 76: 14–22.

47.

Norkus

Miller

Kurtinaitis

Haverkamp

Popov

Prott

F.J.

. (2009a) A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma. Strahlenther Onkol 185: 715–721.

48.

Norkus

Miller

Plieskien

Janulionis

Valuckas

K.P.

(2009b) A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional conformal external-beam radiotherapy for localized prostate adenocarcinoma: a report on the first-year biochemical response. Medicina (Kaunas) 45: 469–475.

49.

Peeters

S.T.H.

Heemsbergen

W.D.

Koper

van Putten

W.L.J.

Slot

Dielwart

M.F.H.

. (2006) Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24: 1990–1996.

50.

Pickett

Kurhanewicz

Coakley

Shinohara

Fein

Roach

(2004) Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 60: 1047–1055.

51.

Pilepich

Asbell

Krall

Baerwald

Sause

Rubin

. (1987a) Correlation of radiotherapeutic parameters and treatment related morbidity – analysis of RTOG Study 77-06. Int J Radiat Oncol Biol Phys 13: 1007–1012.

52.

Pilepich

Krall

Sause

Johnson

Russ

Hanks

. (1987b) Correlation of radiotherapeutic parameters and treatment related morbidity in carcinoma of the prostate – analysis of RTOG study 75-06. Int J Radiat Oncol Biol Phys 13: 351–357.

53.

Pollack

Hanlon

A.L.

Horwitz

E.M.

Feigenberg

S.J.

Konski

A.A.

Movsas

. (2006) Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 64: 518–526.

54.

Pollack

Zagars

G.K.

Starkschall

Antolak

J.A.

Lee

J.J.

Huang

. (2002) Prostate cancer radiation dose response: results of the MD Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53: 1097–1105.

55.

Pucar

Shukla-Dave

Hricak

Moskowitz

C.S.

Kuroiwa

Olgac

. (2005) Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy – initial experience. Radiology 236: 545–553.

56.

Rasch

Barillot

Remeijer

Touw

van Herk

Lebesque

J.V.

(1999) Definition of the prostate in CT and MRI: a multi-observer study. Int J Radiat Oncol Biol Phys 43: 57–66.

57.

Roach

(1996) Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 35: 1011–1018.

58.

Roach

Bae

Speight

Wolkov

H.B.

Rubin

Lee

R.J.

. (2008) Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 26: 585–591.

59.

Sathya

J.R.

Davis

I.R.

Julian

J.A.

Guo

Daya

Dayes

I.S.

. (2005) Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 23: 1192–1199.

60.

Sharifi

Gulley

J.L.

Dahut

W.L.

(2005) Androgen deprivation therapy for prostate cancer. JAMA 294: 238.

61.

Shipley

W.U.

Verhey

L.J.

Munzenrider

J.E.

Suit

H.D.

Urie

M.M.

McManus

P.L.

. (1995) Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 32: 3–12.

62.

Stone

Stock

(2002) Complications following permanent prostate brachytherapy. Eur Urol 41: 427–433.

63.

Sylvester

J.E.

Blasko

J.C.

Grimm

P.D.

Meier

Malmgren

J.A.

(2003) Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int J Radiat Oncol Biol Phys 57: 944–952.

64.

Sylvester

J.E.

Grimm

P.D.

Blasko

J.C.

Millar

Orio

P.F.

III Skoglund

. (2007) 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys 67: 57–64.

65.

Vargas

C.E.

Martinez

A.A.

Boike

T.P.

Spencer

Goldstein

Gustafson

G.S.

. (2006) High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study. Int J Radiat Oncol Biol Phys 66: 416–423.

66.

Villeirs

G.M.

De Meerleer

G.O.

(2007) Magnetic resonance imaging (MRI) anatomy of the prostate and application of MRI in radiotherapy planning. European journal of radiology 63: 361–368.

67.

Wong

W.W.

Vora

S.A.

Schild

S.E.

Ezzell

G.A.

Andrews

P.E.

Ferrigni

R.G.

. (2009) Radiation dose escalation for localized prostate cancer. Cancer 115: 5596–5606.

68.

Zelefsky

M.J.

Chan

Hunt

Yamada

Shippy

A.M.

Amols

(2006) Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176: 1415–1419.

69.

Zietman

A.L.

Bae

Slater

J.D.

Shipley

W.U.

Efstathiou

J.A.

Coen

J.J.

. (2010) Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 28: 1106–1111.

70.

Zietman

A.L.

DeSilvio

M.L.

Slater

J.D.

Rossi

C.J.

Miller

D.W.

Adams

J.A.

. (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA 294: 1233–1239.

Radiation treatment for patients with intermediate-risk prostate cancer

Abstract

Keywords

Introduction

Pretreatment evaluation of patients with intermediate-risk prostate cancer

Clinical trials

Dose-escalation trials

MD Anderson Cancer Center 93-002

Proton Radiation Oncology Group 95–09

Dutch Trial CKTO 6910

Medical Research Council RT01 trial

Radiation therapy with or without hormonal therapy

Dana Farber Cancer Institute Trial

Radiation Therapy Oncology Group 94-08

Trans-Tasman Radiation Oncology Group 96.01

Hypofractionation, stereotactic body radiation therapy and high-dose rate monotherapy

Low-dose rate brachytherapy

High-dose rate brachytherapy boost

Toxicity of radiation therapy and hormone therapy

Toxicity of conventional two-dimensional planning

Toxicity of three-dimensional conformal radiotherapy

Toxicity of intensity-modulated radiation therapy

Toxicity of brachytherapy

Second malignancies

Androgen deprivation therapy

Conclusions

Footnotes

References